Gain Therapeutics, Inc. announced the company saying goodbye to Dr. Xavi Barril, its current Chief Technology Officer, who has been instrumental in guiding the evolution of the company's computational drug discovery platform. Xavi is leaving the world of academia as a professor at the University of Barcelona and his part-time engagement with Gain to join a major pharmaceutical company. The Magellan platform remains in good hands with an experienced team led by Dr. Elena Cubero, who has been working with Xavi and the platform over the last 10 years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.55 USD | +1.59% | +5.37% | -21.90% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.90% | 45.31M | |
+43.36% | 58.06B | |
-5.31% | 40.53B | |
+37.52% | 38.99B | |
+14.75% | 26.7B | |
-12.56% | 26.56B | |
-22.45% | 18.98B | |
+0.04% | 12.17B | |
+25.12% | 12B | |
+26.04% | 11.92B |
- Stock Market
- Equities
- GANX Stock
- News Gain Therapeutics, Inc.
- Gain Therapeutics, Inc. Announces Xavi Barril Leaves as Chief Technology Officer